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Novel folding and stability defects cause a deficiency of human glutathione
transferase omega 1
Abstract
The polymorphic deletion of Glu-155 from human glutathione transferase omega1 (GSTO1-1) occurs in
most populations. Although the recombinant ΔGlu-155 enzyme expressed in Escherichia coli is active, the
deletion causes a deficiency of the active enzyme in vivo. The crystal structure and the folding/unfolding
kinetics of the ΔGlu-155 variant were determined in order to investigate the cause of the rapid loss of the
enzyme in human cells. The crystal structure revealed altered packing around the Glu-155 deletion, an
increase in the predicted solvent-accessible area and a corresponding reduction in the buried surface
area. This increase in solvent accessibility was consistent with an elevated Stern-Volmer constant. The
unfolding of both the wild type and ΔGlu-155 enzyme in urea is best described by a three-state model, and
there is evidence for the more pronounced population of an intermediate state by the ΔGlu-155 enzymes.
Studies using intrinsic fluorescence revealed a free energy change around 14.4 kcal/mol for the wild type
compared with around 8.6 kcal/mol for the ΔGlu-155 variant, which indicates a decrease in stability
associated with the Glu-155 deletion. Urea induced unfolding of the wild type GSTO1-1 was reversible
through an initial fast phase followed by a second slow phase. In contrast, the ΔGlu-155 variant lacks the
slow phase, indicating a refolding defect. It is possible that in some conditions in vivo, the increased
solvent-accessible area and the low stability of the ΔGlu-155 variant may promote its unfolding, whereas
the refolding defect limits its refolding, resulting in GSTO1-1 deficiency.
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Synopsis
The polymorphic deletion of E155 from human GSTO1-1 occurs in most populations.
Although the recombinant ΔE155 enzyme expressed in E. coli is active, the deletion
causes a deficiency of the active enzyme in vivo. The crystal structure and the
folding/unfolding kinetics of the ΔE155 variant were determined in order to
investigate the rapid loss of the enzyme in mammalian cells. The crystal structure
revealed altered packing around the E155 deletion, an increase in the predicted
solvent accessible area and a corresponding reduction in the buried surface area. This
increase in solvent accessibility was consistent with an elevated Stern-Volmer
constant. The unfolding of both the wild type and ΔE155 enzymes in urea is best
described by a three state model, and there is evidence for the more pronounced
population of an intermediate state in the ΔE155 enzymes. Studies using intrinsic
fluorescence revealed a free energy change around 14.4 kcal/mol for the wild type
compared with around 8.6 kcal/mol for the ΔE155 variant, which indicated a decrease
in stability associated the with E155 deletion. Urea induced unfolding of the wild
type GSTO1-1 was reversible through an initial fast phase followed by a second slow
phase. In contrast the ΔE155 variant lacks the slow phase, indicating a refolding
defect. It is possible that in some conditions in vivo, the increased solvent accessible
area and the low stability of the ΔE155 variant may promote its unfolding while the
refolding defect limits its refolding, resulting in GSTO1-1 deficiency.
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Introduction
The Omega class glutathione transferases (GSTO) are among the more recently
identified members of the cytosolic glutathione transferase super family (Board et al.,
2000, Whitbread et al., 2003). Members of the Omega class have a number of novel
features and have been implicated in important metabolic pathways and in the
aetiology of some common neurological diseases (Whitbread et al., 2005, Zakharyan
et al., 2001, Li et al., 2002, Li et al., 2006, Kolsch et al., 2007). In contrast to the other
human GSTs, that have active site tyrosine or serine residues, the Omega class GSTs
have an active site cysteine residue that is essential for its primary catalytic activities
(Board et al., 2000). The Omega class GSTs were originally shown to catalyse
thioltransferase and ascorbate reductase reactions and other studies have shown that
they also catalyse the reduction of monomethylarsonate (MMA), in the methylation
pathway for the disposition of arsenic (Whitbread et al., 2005, Zakharyan et al.,
2001). In addition, recent studies have shown that GSTO1-1 has S-phenacyl
glutathione reductase activity and plays a significant role in the biotransformation of
α-haloketones (Board and Anders, 2007, Board et al., 2008). As well as these
catalytic activities, GSTO1-1 has been implicated in the post-translational processing
and activation of the proinflammatory mediator interleukin-1β (IL-1β) (Laliberte et
al., 2003) and has also been found to act as an inhibitor of cardiac muscle ryanodine
receptor Ca2+ channels (Dulhunty et al., 2001). Interestingly, some genetic mapping
studies have strongly implicated an Omega class GST as a factor influencing the age
at onset of Alzheimer’ and Parkinson” diseases (Li et al., 2002, Li et al., 2003, Li et
al., 2006). Other studies have implicated genetic variation in GSTO1 in vascular
dementia, stroke and cerebrovascular atherosclerosis (Kolsch et al., 2004, Kolsch et
al., 2007). The mechanism by which genetic variation mediates these effects has not
been determined but it could be via effects on the activity or expression of the Omega
class GSTs.
Previous studies have identified a range of polymorphisms in the GSTO genes
(Whitbread et al., 2003, Whitbread et al., 2005, Paiva et al., 2008). While a number
of single nucleotide polymorphisms have been identified in non-coding regions, their
effects on transcription, splicing and mRNA stability have yet to be evaluated
(Mukherjee et al., 2006). In contrast several polymorphisms in coding regions have
been studied in more detail (Whitbread et al., 2003, Whitbread et al., 2005, Paiva et
al., 2008, Tanaka-Kagawa et al., 2003). A polymorphic deletion of three base pairs at
the junction of exon 4 and intron 4 is of particular interest. This deletion could result
in the deletion of Glu155 or a splicing abnormality. This polymorphism has been
identified in a range of different ethnic groups reaching a frequency of over 10% in
one Chinese sample (Whitbread et al., 2003, Yu et al., 2003, Marnell et al., 2003,
Paiva et al., 2008, Schmuck et al., 2005). The deletion occurs in two haplotypes
characterized by a Glu or Lys at position 208 (Schmuck et al., 2005). Recombinant
expression of the Glu155 deletion variant in E.coli affords an active enzyme that has
decreased heat stability (Whitbread et al., 2003, Schmuck et al., 2005). We recently
reported that the T-47D breast cancer cell line is hemizygous for the Glu155 deletion
allele and is deficient in GSTO1-1 enzymatic activity (Schmuck et al., 2008). In
addition, lymphoblastoid cell lines from individuals who were heterozygous for the
Glu155 deletion were reported to have only 50 % of normal catalytic activity with 4nitrophenacylglutathione (4NPG), a specific GSTO1-1 substrate (Schmuck et al.,
2008). These studies suggest that the Glu155 deletion variant is very compromised in
vivo.
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Given the role played by GSTO1-1 in the disposition of α-haloketones (Board and
Anders, 2007) and the targeting of GSTO1-1 by anti-inflammatory drugs (Laliberte et
al., 2003) as well as the proposed role of genetic variation in GSTO1 in the progress
of several neurological disorders (Li et al., 2006, Kolsch et al., 2007), it is apparent
that natural polymorphisms in GSTO1 that affect function are of significant
pharmacogenetic and clinical interest. Consequently we have investigated the effect
of the polymorphic Glu155 deletion on the enzyme’s structure and stability by solving
its crystal structure and studying its unfolding equilibrium.
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Methods
Expression of recombinant GSTO1-1 variants.
In this study several recombinant GSTO1-1 isoenzymes have been studied. There is a
common polymorphism where Asp140 substitutes Ala140. This substitution does not
appear to influence function but since Ala140 is the most common allele we refer to it
as the wild type and the substituted variant as A140D. In each case the Glu155
deletion variants have alanine at residue 140. cDNAs encoding GSTO1-wild type,
GSTO1-A140D, GSTO1 ΔE155/E208 and GSTO1 ΔE155/K208 were cloned into the
pHUE expression vector and transfected into E. coli BL21(DE3). The expression and
purification of recombinant proteins using the pHUE vector and ubiquitin cleavage
techniques have been previously described in detail (Baker et al., 2005). Briefly, the
recombinant 6xHis-Ubiquitin-GSTO fusion protein was purified by chromatography
on Ni-agarose. The His-Ubiquitin fusion moiety was removed by digestion with the
catalytic core of Usp2, and re-chromatography on Ni-agarose. The purified proteins
were dialysed against 20 mM Tris pH8, 60 mM NaCl, 5 mM dithiothreitol for storage
and crystallization experiments.
Crystallization and structural determination of GSTO1-1 ΔE155/E208.
Unsuccessful attempts were made to grow crystals of GSTO1 ΔE155 under identical
conditions to those reported for the native enzyme (Board et al., 2000). The protein
was therefore subjected to the Index screen (Hampton Research) to find new
conditions. The vapour diffusion technique was employed using a 96 well, sitting
drop crystallization tray (Nunc, Roskilde, Denmark). For screening, 1 µL of protein
(12 mg/ml) was mixed with 1 µL of 10mM glutathione and 1 µL of reservoir solution.
Reservoirs contained 100 µl of each screen condition. The tray was then sealed with
Crystal Clear tape (Hampton Research) and allowed to equilibrate at 18° C. After 6
days, crystals were observed in condition 62 (0.1 M Tris pH 8.5, 0.2 M trimethyl
amine N-oxide dihydrate, 20 % (w/v) polyethylene glycol monomethyl ether 2000).
Scaling up was achieved via a doubling of the overall crystallisation volume using the
same method. Crystals were flash frozen at 100K using an Oxford cryostream.
Cryoprotection was by sequential transfer to artificial mother liquor containing 20 %
glycerol by 5 % increments. The crystals were then transferred to liquid nitrogen and
stored until subsequent data collection using a Rigaku RU-200 rotating anode X-ray
generator with mirror optics and Mar345 desktop beamline. Processing of data
collected from a single crystal was performed using the programs DENZO and
SCALEPACK (Otwinowski and Minor, 1997). Phase information was obtained by
molecular replacement using the structure of the native enzyme (Board et al., 2000) as
a search model with the program MOLREP (Vagin and Teplyakov, 1997). Model
rebuilding to match experimental density, including the deletion of E155, was
achieved with the programs O (Jones et al., 1991) and Coot (Emsley and Cowtan,
2004) and alternated with restrained refinement by the program REFMAC
(Murshudov et al., 1997). The program PHENIX (Adams et al., 2002) was then
employed for the final stages of refinement using the simulated annealing option with
default settings. Finally, the program MolProbity (Davis et al., 2007) was used to add
hydrogens to the structure and diagnose Asn/Gln/His flips prior to validation
deposition, PDB accession code 3LFL.
Spectroscopy and activity measurements
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All fluorescence data were measured on Perkin-Elmer LS 50B Luminescence
Spectrophotometer (Perkin Elmer, USA). Tryptophan fluorescence was used to
monitor structural change. Excitation was at 295 nm and fluorescence was recorded in
the range of 305 nm – 430 nm. ANS (1-anilino-8-naphthalene sulfonate) was
added to protein samples in a molar ratio of 50:1 (Erhardt and Dirr, 1995), and
equilibrated for 50 min for complete interaction. ANS binding spectra were recorded
in the range of 405 nm – 540 nm with excitation at 390nm. Enzymatic activity was
determined with the GSTO1-1 specific substrate S-(4-nitrophenacyl)-glutathione
(4NPG) as described previously (Board et al., 2008).
Tryptophan fluorescence quenching by acrylamide
Acrylamide (8M) was added to 1uM GSTO1 proteins (calculated by a molar
extinction coefficient of 82800 M-1cm-1 at 280nm) to achieve different concentrations,
and mixed thoroughly. Fluorescence intensities were monitored at 336 nm. Each
protein sample was repeated at least 3 times, and then averaged. Quenching data were
analyzed by the Stern-Volmer equation (Lakowicz, 1986):
Fo
−1 = K sv [Q] (1)
F
where Fo and F are the fluorescence intensities before and after the addition of
acrylamide. [Q] is the acrylamide concentration, and KSV is the Stern-Volmer
constant, which can reflect the burial of tryptophan residues and thus indicate the
protein accessibility. €
Circular dichroism measurement
Circular dichroism (CD) was monitored on Chirascan™ Circular Dichroism
Spectrometer (Applied Photophysics) using a cuvette with a 0.1cm light path.
Ellipticity at 222nm was collected and plotted against variation of urea concentration.
Equilibrium unfolding experiments
Urea-induced unfolding experiments were performed in 20 mM sodium dihydrogen
phosphate with 40mM ammonium phosphate, pH 7.0, at 1 µM protein concentration.
To reach equilibrium, protein samples with different urea concentrations (0-9 M) were
incubated at 30° C for 5 hours, and then cooled down to room temperature for
intrinsic fluorescence, ANS binding, and circular dichroism measurements. For the
analysis of the intrinsic fluorescence the ratio of emission intensity at 333 nm (folded
protein) and 355 nm (unfolded protein) was determined, and the relative intensity at
475 nm was determined for ANS binding. Data from 3-4 separate replicates from two
purification batches of each protein were averaged.
Urea unfolding curves were fitted to a two-state (N2↔2U) unfolding model or a threestate model (N2↔I↔2U)(Szpikowska and Mas, 1996, Gloss and Matthews,
1997)using SigmaPlot version 10.0, and the equilibrium fractions of native,
intermediate, and denatured state were solved (Gloss and Matthews, 1997) .
Protein refolding
Refolding of unfolded proteins was detected using 4NPG reduction assay and
tryptophan fluorescence recovery. For activity reversibility, proteins were brought to
a concentration of 1 µM in 6 M urea and allowed to unfold for 5hrs at 30° C. The
proteins were then diluted 6 times, and allowed to refold at room temperature.
Enzyme activity was determined after 1hr. When refolding was monitored by intrinsic
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fluorescence, 30uM proteins were fully unfolded in 7.4 M urea. The enzymes were
then diluted 10 times, and the emission intensities were recorded every minute.
Results
Crystal structure of GSTO1 ΔE155/K208
To determine whether the deletion of E155 caused any significant structural
alterations, we crystallized and solved the structure of the GSTO1 ΔE155/E208
variant. The crystals were found to be of a different space group (P21212) compared
with the native enzyme (P3121) and diffracted to 2.1 Å. Table 1 summarizes the
crystallographic data and model statistics.
Molecular replacement in MOLREP (Vagin and Teplyakov, 1997) revealed 3
monomers in the asymmetric unit. Monomer A sits adjacent to a crystallographic twofold axis so as to form a physiological dimer with its crystallographic partner (A-A).
Monomers B and C form a second dimer (B-C). The overall topology is similar to that
of the wild-type enzyme, except for the following: the deletion of residue E155 results
in the premature termination of helix α5 and a conformational change in the helix α5
to α6 loop (Figure 1A). Its subsequent removal from the search model required
significant rebuilding of the associated residues, a process coupled with restrained
refinement until local aberrations in the mFo-DFc electron density map were removed.
As shown in figure 1B, several perturbations in the surrounding structure contribute to
this enzyme’s altered phenotype. The hydrophobic interactions (not shown in this
figure) of adjacent residues Val156 and Leu157 have been disrupted by Cα
translations of 5.3 Å and 8.0 Å, respectively. This has caused Val156 to be exposed to
solvent. The translocation of Leu157 on the other hand, has produced a new
interaction with Leu119 and of particular interest, an interaction with the side chain of
Pro68 from the other subunit in the physiological dimer, effectively creating a new
interaction at dimer interface. In addition, the Thr158 Cα has shifted by 6.4 Å,
allowing its side chain to occupy the position previously inhabited by that of Val156.
Such changes have contributed to an increase in the water accessibility of Leu157 to
over 100 Å2 and an increase in the buried area at the interface of twice this magnitude.
In total there are only 7 contacts ≤ 3.5 Å between residues 150-164 of α5 and residues
192-202 of loop-α7 in the ΔE155/E208 enzyme, 18 fewer than in the wild type
enzyme. The altered packing has likely played a role in the observed refolding
anomaly of E155 deletion variants discussed below. The alterations in the dimer
interface do not appear to preclude the formation of heterodimers between wild type
and deletion-containing monomers.
The potential flexibility of the C-terminal region can be observed in the ΔE155/E208
structure. Comparison of the active site of monomer A with the wild type enzyme
reveals a rotation of the putative ‘H-site’ residue, Trp222, resulting in the removal of
its indole nitrogen from the binding pocket, increasing its hydrophobic character. As
shown in figure 2A, the entrance to the binding pocket has also been partially
occluded by the movement of Arg183 and Tyr229. Helix α9, of monomer A which
forms part of the active site, has shifted away from the GSH binding pocket (G-site),
possibly to accommodate movements in residues Tyr229 and Trp222 (figure 2A).
While the B and C monomers display similar structural changes relating to the
deletion site, it is the conformational shift of their C-termini that is most remarkable.
As shown in figure 2B helix α9 of monomer B has moved toward the G-site and
rotated so that Leu228 and Tyr229 block the H-site entrance. There is a significant
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rearrangement of Trp222, which has been excluded from the H-site and is stacked
against helix α6, exposed to bulk solvent. The net effect is to make the ‘H-site’
smaller. Furthermore, the last 10-14 residues forming helix α10 and its connecting
loop fail to show substantial 2mFo-DFc density in monomers B and C. These
significant changes do not appear to be a consequence of crystal packing, as the
crystal contacts in each monomer are different. The different conformations seen in
the two dimers (A-A and B-C) may therefore reflect the conformational space
sampled in solution. Such helix α9 movements may be crucial to the binding of
ligands of variable size and shape, for example mono methylarsonate and
dehydroascorbate.
Equilbrium unfolding /folding of GSTO1 ΔE155/E208
Initially, to determine if the deletion of E155 caused subtle changes to the enzyme’s
conformation in solution, the Stern-Volmer constant (KSV) was calculated by
quenching the natural tryptophan fluorescence using acrylamide. Linear Stern-Volmer
plots revealed a clear difference between the variant enzymes with the E155 deletion
and the enzymes with A or D at residue 140 (Figure 3). This difference is reflected
numerically in KSV for each enzyme (5.258 (R2 = 0.9989) for wild type (A140), 5.840
(R2 = 0.9982) for A140D, 6.975 (R2 = 0.999) for ∆E155/E208, and 7.299 (R2 =
0.9979) for ∆E155/K208). The data suggest that the deletion of E155 increases the
accessibility of tryptophan residues. This is supported by calculations from the
crystal structure of increased accessible surface area (ASA) of total protein and of
tryptophan residues in the ΔE155 (Table 2).
Characterization of urea-induced unfolding.
The unfolding of the GSTO1-1 enzymes in the presence of urea was examined using
tryptophan fluorescence, circular dichroism (CD) and ANS binding (Figure 4). The
fluorescence data (Figure 4a), for the wild type and A140D enzymes indicate that they
do not begin unfolding before the urea concentration exceeds 3.7 M, and appear to
exhibit a single transition phase. In contrast, the equilibrium denaturation of the
∆E155 enzymes start to show an unfolding signal below 1M urea, and have a biphasic
transition profile. The difference in the unfolding profiles between the E155
containing and ∆E155 enzymes is also observed for the CD data (Figure 4b) where
the ∆E155 enzymes start losing their helical secondary structure content at the lowest
concentrations of urea. It is also of interest to note that at the starting point of the
unfolding curve in Figure 4b the ∆E155 variants have a lower helical content than the
wild type enzymes, which is consistent with the ∆E155/E208 structure. The data
from the ANS binding measurements (Figure 4c) provides the clearest evidence that
the unfolding profiles of the ∆E155 enzymes are different to the E155 containing
enzymes. Using tryptophan fluorescence, protein concentration dependence was
observed for the transition phase of the wild type enzyme and the second transition
phase of the ∆E155/E208 enzyme (figure 5). Taken together, this data suggested that
the equilibrium unfolding of the wild type and A140D enzymes might be described by
a two state model (N2↔2U) while the unfolding of the ∆E155 enzymes might best be
described by a three state unfolding model (N2↔I↔2U).
Tryptophan fluorescence and ANS binding data from the ∆E155 enzymes were fitted
to a three state model with an R2>0.999, while the fitting of fluorescence data from
the wild type and A140D enzymes to a two state model gave a slightly lower R2
(0.9986 and 0.9974 respectively) and lower free energy values (Table 3) that were
inconsistent with the previously observed lower thermal stability for ∆E155 enzymes
(Whitbread et al., 2003). When the same three state model was used to re-fit the data
from the wild type and A140D enzymes, a better fit (figure 4a) with a higher R2
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(>0.9993) was obtained. Based on the fitting result (Table 3), equilibrium
denaturation of the wild type and A140D proteins appears to be better described by a
three state unfolding model. Given the protein concentration dependence of the
transition phase of both enzymes (Figure 5) it appears that the transition intermediate
formed by the ∆E155 enzymes is likely to be a dimer. It is not clear whether this is the
case for wild type and A140D enzymes.
The population of the transition intermediate appears to differ significantly between
the E155 containing and ∆E155 enzymes. Based on the three state model, the
fractions of the transitional intermediate, and the native and unfolded states at
different urea concentrations were calculated and plotted (figure 4d-4f). The
population of intermediate formed by the wild type and A140D enzymes is largely
overlapped by the unfolded fraction suggesting that this intermediate is very
transitory, and may indicate the reason why there is no obvious intermediate state
reflected in the equilibrium unfolding curves. In contrast, the intermediate of the
∆E155 enzymes is clearly distinguishable at lower urea concentrations and has an
increased area of exposed hydrophobic surface as illustrated by the ANS binding data
(Figure 4c).
Thermodynamic analysis of urea-induced unfolding.
The thermodynamic parameters for the E155 containing and E155 deletion enzymes
are shown in Table 3. The three state fit of tryptophan fluorescence data, from the
wild type and A140D enzymes provided a similar total free energy change of 14.4
kcal/mol and 14.3 kcal/mol respectively, which is larger than that obtained for the
∆E155 enzymes (8.6 kcal/mol and 8.7 kcal/mol for ∆E155/E208 and ∆E155/K208
respectively). Similar results were obtained from the ANS binding data. The main
difference between the wild type and the ΔE155 variant occurs in the initial unfolding
to the transition intermediate. Studies using intrinsic fluorescence revealed a free
energy change for this first transition of around 8.5kcal/mol for the wild type
compared with around 2.8 kcal/mol for the ΔE155 variant. These data suggest that the
enzymes with the E155 deletion are less stable than E155 containing enzymes, and the
lower stability of ∆E155 enzymes comes primarily from a propensity to enter the first
transition phase.
Reversibility of unfolding
The ability of the enzymes to re-fold after urea-induced unfolding was evaluated by
fluorescence recovery and the restoration of catalytic activity (Figure 6). The two
methods used here to monitor the refolding gave the similar results. Refolding of the
wild type E155 containing enzymes was essentially complete after 1 hour with the
recovery of around 95 %. In contrast the enzymes with the E155 deletion regained
only around 70 % of their original activity or fluorescence intensity over this period.
The refolding curve of wild type and A140D enzymes monitored by fluorescence can
be fitted to a two-phase exponential equation, which respectively gave 3.18 ± 0.57
min-1 and 3.34 ± 0.52 min-1 for k1, and 0.22 ± 0.06 min-1and 0.27 ± 0.05 min-1 for k2
with an R2=0.9984 and 0.9992. However, refolding of the ∆E155/K208 variant
followed single-phase exponential kinetics, with a rate of 4.04 ± 0.80 min-1 (R2 =
0.9978). This suggests that the ∆E155 variants still have a similar fast refolding phase
like the wild type and A140D enzymes, but have lost the second slow refolding phase
as shown in figure 6.
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Discussion
Previous studies have indicated that the polymorphic deletion of E155 causes a
deficiency of GSTO1-1 in cell lines but the mechanism causing this deficiency is not
clear. As the deletion can potentially alter splicing at the end of exon 4 we previously
undertook Northern blotting analysis to eliminate a splicing defect as a cause of the
GSTO1-1 deficiency (Schmuck et al., 2008). That study showed that T47D breast
cancer cells that are hemizygous for the E155 deletion allele produce mRNA of the
appropriate size, suggesting that abnormal splicing is unlikely to be the cause of the
deficiency. Previous pulse chase studies in T47D cells indicate that the E155 deletion
protein has a shorter than normal T1/2 (Schmuck et al., 2008). Although this variant
can be expressed as an active enzyme in E coli, the recombinant enzyme is relatively
heat sensitive (Schmuck et al., 2008). Given the clinical interest in GSTO1-1 we
were interested to determine the mechanism by which the E155 deletion mediates this
deficiency.
The crystal structure indicated that the deletion of E155 caused only small
perturbations of the overall protein fold. Although there is a slight decrease in the
volume and apparent accessibility of the H site, the distinct structural forms of ΔE155
dimers observed in the crystal structures point toward increased flexibility of the
protein. This may explain the previously observed increase in catalytic activity of
ΔE155 mutants (Table 4), as conformations suitable for binding and catalysis of
diverse substrates are more accessible to the flexible mutant protein. The catalytic
activity of the recombinant ΔE155 enzymes and the absence of immunologically
detectable GSTO1-1 in T47D cells suggest that the deletion may cause a defect in
stability or folding rather than a loss of function. We found several structural factors
that could have a deleterious impact on stability including the increase in the water
accessible surface area, reduction in buried hydrophobic surface area, and the large
decrease in molecular contacts between helies α5 and α7. Even the increased buried
area of dimer interface was not a positive factor because of the concomitant increase
in the surface area of solvent exposed hydrophobic residues.
The determined free energy change ΔG 0N→ U supports the lower stability of the ∆E155
enzymes.. We also found evidence that at low urea concentrations the ∆E155 enzymes
form a transitional intermediate that is not significantly populated by the E155
containing enzymes. The unfolding intermediate formed by the ∆E155 enzymes
€ more hydrophobic area exposure revealed by the ANS
appears to be a dimer with
binding data. The nature of the intermediate formed by the E155 containing enzymes
is difficult to identify with the present data.
The capacity of the E155 deletion variants to refold after complete unfolding in urea
was limited compared with the E155 containing A140 and D140 enzymes (figure 6).
This limitation only occurred during the second slow phase of refolding. Since
refolding is usually thought to be the reverse of unfolding, the refolding of the E155
deletion enzymes is probably limited by the population of the transitional
intermediate. As mentioned above, the intermediate has a larger exposed hydrophobic
surface, which probably promotes precipitation or prevents further refolding of the
protein resulting in the lack of second slow phase for the ∆E155 enzymes.
Intracellular proteins are dynamic and may be subjected to conformational changes
under different intracellular conditions. It is possible that the increased accessibility to
solvent and decreased contacts in the E155 deletion enzyme may promote unfolding
and restrict refolding by presenting a barrier of increased hydrophobic surface
exposure, leading to an dynamic equilibrium that favours an unfolded state in vivo.
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We therefore conclude that the deletion of E155 causes GSTO1-1 deficiency by its
low stability, resulting from its increased propensity to unfold, and a novel
mechanism that inhibits refolding. The structural characteristics the deletion mutant,
high ASA and less buried hydrophobic area and loose packing around ∆E155 agree
with these observations. The results help us to understand the impact of the E155
deletion allele on the level of GSTO1-1 activity in vivo, which may contribute to the
observed association of GSTO1 with the age at onset of Alzheimers disease and the
activation of the pro-inflammatory cytokine IL1β.
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Table 1. X-Ray Data Collection and Refinement Statistics

Space group

P21212

Unit-cell parameters (Å)

a = 73.0, b = 201.9, c = 53.4

Reflections measured / unique 389373 / 44498
Resolution range (Å)

36.51-2.10 (2.18-2.10†)

R-merge (%)

12.8 (37.0†)

Completeness

94.4 (80.7†)

Mean I/σI

21.4 (3.5†)

R / Rfree (%)

19.91 / 26.05

rmsd bonds (Å)

0.008

rmsd angles (°)

1.120

PDB Accession code

3LFL

†

, the highest resolution bin
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Table 2. Interface and surface analysis of ΔE155/E208 and wild type crystal structure
Solved
residues

SA of
dimer(Å2)

Total buried
area of
dimer(Å2)
3859.9

Total SA of
Trp residues
in dimer(Å2)
32.48

Buried area of
dimer
interface(Å2)
1885.6

GSTO1
Ser520961.5
wild type
Leu241
(1eem)
ΔE155
Ser521639.1
3317.3
33.74
2116.6
monomer
Leu240
A
All calculations come from online PISA (Krissinel and Henrick, 2007) of EBI
services
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Table 3. Thermodynamic parameters characterising the urea-induced unfolding transition monitored by tryptophan fluorescence and ANS binding.

ΔG 0N→ U (kcal/mol)
WT
A140D
WT
A140D

€

6.41±0.32
5.15±0.36
8.21±0.71
7.78±1.06

€

Two state fita
mN→ U (kcal/mol/M)
Tryptophan fluorescence
1.32±0.07
1.05±0.08
ANS binding
1.59±0.14
1.47±0.20

ΔG 0N→ U (kcal/mol)

[urea]1/ 2 (M)

€

4.86±0.03
4.92±0.06

€

5.17±0.04
5.30±0.07

Three state fitb
ΔG 0N→ I (kcal/mol) mN→ I(kcal/mol/M) [urea]1/ 2,1 (M) ΔG 0I→ U (kcal/mol) mI→ U (kcal/mol/M)
Tryptophan fluorescence
WT
8.51±0.46
1.81±0.11
4.69±0.06
5.91±2.42
1.00±0.36
A140D
9.16±0.82
2.02±0.20
4.55±0.09
5.14±1.67
0.87±0.26
€
€
€
€
€
€
∆E155/E208
2.84±0.79
1.48±0.37
1.92±0.12
5.78±0.35
1.37±0.08
∆E155/K208
3.34±0.97
1.80±0.49
1.86±0.11
5.39±0.31
1.29±0.07
ANS binding
WT
7.65±2.43
2.45±0.80
3.11±0.11
7.07±0.42
1.44±0.08
A140D
5.43±2.41
2.10±0.91
2.58±0.14
5.58±0.57
1.13±0.12
∆E155/E208
3.51±1.55
1.95±0.77
1.77±0.17
6.54±0.58
1.55±0.13
∆E155/K208
3.89±1.64
1.88±0.79
2.06±0.15
4.98±0.62
1.27±0.14
a
b
fitted according to the two state model (N2→2U). fitted to the three state model via a dimeric intermediate.

6.41
5.15
8.21
7.78

[urea]1/ 2,2 (M)
5.91±0.33
5.94±0.22
4.22±0.03
4.19±0.03

14.42
14.3
8.62
8.73

4.91±0.03
4.93±0.06
4.20±0.04
3.92±0.07

14.72
11.01
10.05
8.87
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Table 4. The activity of recombinant wild type and delE155 GSTO1-1 variants with a range of substrates.
Enzyme

CDNB

Thiol transferase

Dehydroascorbate

Monomethylarsonate Dimethylarsonate

2,4-DCPG

hGSTO1-1

0.047±0.01
0.039±0.01

2±0.21
2.6±0.26

0.13±0.005

0.33±0.037

0.12±0.006

1.3±0.1

6±0.09

0.25±0.045

0.65±0.007

0.3±0.014

1.3±0.05

4.8±0.07
3.6±0.36

0.21±0.03

0.67±0.066

0.37±0.015

1.1±0.03

∆E155, E208
∆E155, K208 0.063±0.01

All activities shown as µmol/min/mg, mean±SD. CDNB ; 1-chloro-2,4,dinitrobenzene. 2,4-DCPG ; S-(2,4-dichlorophenacylglutathione).
All data compiled from (Board and Anders, 2007, Whitbread et al., 2003, Schmuck et al., 2005)
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Figure legends
Figure 1: Structural changes induced by the deletion of E155. (A) A view
perpendicular to the crystallographic two-fold axis of the native structure (translucent
yellow), the ∆E155 A monomer (cyan) and the non-crystallographic two-fold axis of
the ∆E155 B and C monomers (magenta) which produce the GSTO1-1 physiological
dimer. The position of E155 and GSH are shown with stick representation. (B) A
closer inspection of the deletion site within the ∆E155 A-monomer (cyan) compared
with the wild-type enzyme (yellow). Changes to the associated residue side chain
conformations in stick representation. The new interaction formed at the dimer
interface is also visible. The adjacent monomer is shown in magenta. The figures
were generated using PyMol (http://www.pymol.org.)

Figure 2: The flexibility of helix α9 observed in the ΔE155 structure. (A) A closer
view of the A monomer active site reveals several key differences compared with the
native enzyme. Of most interest is the different rotamer adopted by Trp222,
dramatically increasing the hydrophobicity within the conserved ‘H-site’. The ΔE155
A-monomer is shown in cyan compared with the wild-type enzyme in yellow. (B)
Comparison of the native structure to that of the B monomer reveals much more
pronounced structural change. Helix α9 has shifted towards the site of glutathione
binding by several Angstroms, dramatically reducing the size of the ‘H-site’. The
ΔE155 B-monomer is shown in magenta with the overlayed native structure in
yellow. The figures were generated using PyMol (http://www.pymol.org.)
Figure 3. Tryptophan fluorescence quenching by acrylamide. The experimental
values and trend lines are shown as (●) wild type, (¡) A140D, (▼) ∆E155/E208, and
(r) ∆E155/K208.
Figure 4. The equilibrium unfolding of GSTO1-1 in urea. Unfolding was monitored
by (a) tryptophan fluorescence expressed as the ratio of fluorescence at 333nm to the
fluorescence at 355nm, (b) ellipticity at 222nm of circular dichroism, and (c) relative
intensity of ANS binding. The three state curve fits of N2↔I↔2U are shown in (a)
and (c). The inset in (a) is the 2-state fitting result for wild type and A140D, which is
less consistent with the experimental values at high urea concentration compared with
the 3-state fit. The calculated population of the native, intermediate, and unfolded
states of GSTO1-1 as a function of urea concentration are plotted for wild type and
A140D (d, solid line for wild type and dashed line for A140D), ∆E155/E208 (e), and
∆E155/K208 (f). The experimental values for each enzyme are shown as (●) wild
type, (¡) A140D, (▼) ∆E155/E208, and (r) ∆E155/K208.
Figure 5. The protein concentration dependence of equilibrium unfolding of GSTO11 variants in urea. The unfilled symbols represent determinations at 1µM protein and
the filled symbols represent determinations at 8µM protein.
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Figure 6. Refolding of GSTO1 variants. Symbols and solid curves represent the
recovery of fluorescence. The right-hand columns show the recovery of activity with
4-NPG as a substrate (mean + SD).
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